University Hospitals, today announced it, has selected the 2bPrecise® platform to bring genomic data into the clinical workflow, impacting patient care in both acute and ambulatory settings. The 2bPrecise platform is an offering from 2bPrecise LLC, a wholly owned subsidiary of Allscripts. University Hospitals (UH) serves the needs of patients through an integrated network of 18 hospitals, more than 50 outpatient health centers and 200 physician offices in 15 counties throughout northern Ohio.
Read More
Interpreta, higi, Partners to Integrate Biometric Data for Patient Engagement
Interpreta and higi are announcing a partnership to integrate biometric data from higi with clinical, claims and genomic data from Interpreta. The integration will enable patients and their physicians to increase engagement and share healthcare data (on blood pressure, pulse, BMI, weight, body composition, and self-screening questions) gained at higi retail stations and prioritized within Interpreta in real time.This will enable physicians and insurers to leverage a patient’s biometrics data,
Read More
Genomic Analysis Startup Genoox Raises $6M to Expand in the US Market
Genoox, the genomic analysis company making it easier for doctors, clinicians, and researchers to analyze and act on genetic sequencing data has raised $6 million in funding led by Inimiti Capital Partners and Glilot Capital Partners. With this investment, Genoox will also be expanding their genomic services into the U.S. healthcare market, providing medical facilities with innovative solutions to help solve real and pressing healthcare problems. Genoox has an international footprint, with a
Read More
Mount Sinai Spinout Sema4 Launches to Revolutionize Clinical Diagnostics
Sema4, a new startup that has spun out of Mount Sinai Health System has officially launched today that aims to use genomic and clinical data to empower more informed health decisions and enhance care and wellness. Formerly the Mount Sinai Genetic Testing Lab at the Icahn School of Medicine at Mount Sinai, Sema4 is constructing a more comprehensive picture of health by combining a wealth of clinical experience that informs the answers that patients and providers are seeking, the world-class
Read More
Penn Medicine’s Abramson Cancer Center Launches Initiative to Improve & Personalize BRCA Mutations
Cancer experts at the Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania have announced a new collaboration with Tempus to improve and personalize treatment for patients with heritable BRCA mutations. Tempus, a technology company focused on helping doctors personalize cancer treatment will analyze the molecular and clinical data of patients who were treated at the Basser Center and harbor a BRCA mutation using machine learning and advanced
Read More